Tonix Pharmaceuticals (NASDAQ:TNXP) received a new European use patent for TNX-601, providing intellectual property protection until 2029 for the treatment of neurocognitive dysfunction associated with corticosteroids.
TNX-601 is a pre-IND-stage drug being developed for daytime treatment of PTSD and the cognitive side effects of steroid therapies, including sedation, confusion, mental fatigue and the inability to concentrate. Tonix plans to initiate a Phase 1 clinical trial outside of the U.S. later this year.
Tonix was previously granted use patents for TNX-601, its structural analogs and salts, in the U.S., Canada and Europe.
